A 52-Week Study of Dose Adjusted Subcutaneous Testosterone Enanthate in Oil Self-Administered via Disposable Auto-Injector

Kaminetsky, Jed; McCullough, Andrew; Hwang, Kathleen; Jaffe, Jonathan S.; Wang, Christina; Swerdloff, Ronald S.

doi:10.1016/j.juro.2018.09.057

Cited by 25 publications

(17 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…47,86,130,131 In contrast, a weekly subcutaneous, autoinjectable T formulation received FDA approval in 2018 and is able to achieve a more stable PK profile resulting in less fluctuation in serum T levels. 132,133 The effect of normalizing T levels on the incidence of MI and mortality in 83,010 male veterans with documented low TT levels has recently been investigated. 134 The participants were divided into 3 groups: those with normal T levels (defined as within the reported laboratory reference range) after TTh; those that did not achieve normal T levels after TTh; and those that did not receive TTh.…”

Section: Insufficient Repletion Of Serum T Levelsmentioning

confidence: 99%

Testosterone Therapy and Cardiovascular Risk: A Critical Analysis of Studies Reporting Increased Risk

Khera

Miner

Jaffe

et al. 2021

The Journal of Sexual Medicine

View full text Add to dashboard Cite

Section: Insufficient Repletion Of Serum T Levelsmentioning

confidence: 99%

Testosterone Therapy and Cardiovascular Risk: A Critical Analysis of Studies Reporting Increased Risk

Khera

Miner

Jaffe

et al. 2021

The Journal of Sexual Medicine

View full text Add to dashboard Cite

“…Subcutaneous. Recently, formulations of testosterone cypionate or enanthate have been used for subcutaneous administration with success in female-to-male transgender patients (Spratt et al, 2017), and a 75-mg subcutaneous auto-injector for weekly self-administration of testosterone enanthate has been tested with satisfactory efficacy and safety in adults (Kaminetsky et al, 2019). Similarly, the 1,000-mg testosterone undecanoate formulation used for IM administration has recently been tested subcutaneously; while the pharmacokinetic features were similar to those observed with IM administration, pain after injection was greater when used subcutaneously, which lead to a lesser acceptability (Turner et al, 2019).…”

Section: Formulations Used For Androgen Therapymentioning

confidence: 99%

Androgen Treatment in Adolescent Males With Hypogonadism

Rey

Grinspon

2020

Am J Mens Health

View full text Add to dashboard Cite

During adolescence, androgens are responsible for the development of secondary sexual characteristics, pubertal growth, and the anabolic effects on bone and muscle mass. Testosterone is the most abundant testicular androgen, but some effects are mediated by its conversion to the more potent androgen dihydrotestosterone (DHT) or to estradiol. Androgen deficiency, requiring replacement therapy, may occur due to a primary testicular failure or secondary to a hypothalamic–pituitary disorder. A very frequent condition characterized by a late activation of the gonadal axis that may also need androgen treatment is constitutional delay of puberty. Of the several testosterone or DHT formulations commercially available, very few are employed, and none is marketed for its use in adolescents. The most frequently used androgen therapy is based on the intramuscular administration of testosterone enanthate or cypionate every 3 to 4 weeks, with initially low doses. These are progressively increased during several months or years, in order to mimic the physiology of puberty, until adult doses are attained. Scarce experience exists with oral or transdermal formulations. Preparations containing DHT, which are not widely available, are preferred in specific conditions. Oxandrolone, a non-aromatizable drug with higher anabolic than androgenic effects, has been used in adolescents with preserved testosterone production, like Klinefelter syndrome, with positive effects on cardiometabolic health and visual, motor, and psychosocial functions. The usual protocols applied for androgen therapy in boys and adolescents are discussed.

show abstract

“…70 Treatment with T might also promote the possibility of adverse cardiovascular events. 70,71 Fetal growth has a role in the programming of adult cardiometabolic disorders, which are linked to decreased T levels in males. 72 Fetal growth and fetal androgen exposure could predetermine T levels in men, although how is unknown, as the adult Leydig cells do not differentiate until puberty.…”

Section: Androgens In Cmsmentioning

confidence: 99%

The Effects of Androgens on Cardiometabolic Syndrome: Current Therapeutic Concepts

et al. 2020

View full text Add to dashboard Cite

Introduction: Cardiometabolic syndrome (CMS), as a bunch of metabolic disorders mainly characterized by type 2 diabetes mellitus (T2DM), hypertension, atherosclerosis, central adiposity, and abdominal obesity triggering androgen deficiency, is one of the most critical threats to men. Although many significant preclinical and clinical findings explain CMS, new approaches toward common pathophysiological mechanisms and reasonable therapeutic targets are lacking. Aim: To gain a further understanding of the role of androgen levels in various facets of CMS such as the constellation of cardiometabolic risk factors including central adiposity, dyslipidemia, insulin resistance, diabetes, and arterial hypertension and to define future directions for development of effective therapeutic modalities. Methods: Clinical and experimental data were searched through scientific literature databases (PubMed) from 2009 to October 2019. Main Outcome Measure: Evidence from basic and clinical research was gathered with regard to the causal impact and therapeutic roles of androgens on CMS. Results: There are important mechanisms implicated in androgen levels and the risk of CMS. Low testosterone levels have many signs and symptoms on cardiometabolic and glycometabolic risks as well as abdominal obesity in men. Clinical Implications: The implications of the findings can shed light on future improvements in androgen levels and add potentially predictive risk for CMS, as well as T2DM, abdominal obesity to guide clinical management in the early stage. Strengths & Limitations: This comprehensive review refers to the association between androgens and cardiovascular health. A limitation of this study is the lack of large, prospective population-based studies that analyze the effects of testosterone treatment on CMS or mortality. Conclusion: Low testosterone levels have several common features with metabolic syndrome. Thus, testosterone may have preventive role in the progress of metabolic syndrome and subsequent T2DM, abdominal obesity, and cardiovascular disease and likely affect aging men's health mainly through endocrine and vascular mechanisms. Further studies are necessary to evaluate the therapeutic interventions directed at preventing CMS in men. Kirlangic OF, Yilmaz-Oral D, Kaya-Sezginer E, et al. The Effects of Androgens on Cardiometabolic Syndrome: Current Therapeutic Concepts. Sex Med 2020;8:132e155.

show abstract

A 52-Week Study of Dose Adjusted Subcutaneous Testosterone Enanthate in Oil Self-Administered via Disposable Auto-Injector

Cited by 25 publications

References 0 publications

Testosterone Therapy and Cardiovascular Risk: A Critical Analysis of Studies Reporting Increased Risk

Testosterone Therapy and Cardiovascular Risk: A Critical Analysis of Studies Reporting Increased Risk

Androgen Treatment in Adolescent Males With Hypogonadism

The Effects of Androgens on Cardiometabolic Syndrome: Current Therapeutic Concepts

Contact Info

Product

Resources

About